UK Biotech Company Awarded Orphan Status for ALS Treatment

Privately owned UK biotech company Daval International Limited has been informed by Australia’s Therapeutic Goods Administration (TGA) that its anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Click here to read more.

Share this: